The table below shows HALOZYME THERAPEUTICS, INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
$180.08M
$154.22M
$129.43M
$86.96M
$47.80M
$58.30M
Capital expenditure
$3.74M
$950.00K
$3.54M
$11.38M
$490.00K
$270.00K
Investing cash flow
-$2.88M
-$90.42M
-$82.68M
-$60.16M
-$49.30M
-$45.25M
Dividends paid
-
-
-
-
HALO operating cash flow (10-K history)
HALOZYME THERAPEUTICS, INC. reported operating cash flow of $651.56M for fiscal year 2025. That is up 36.0% from $479.06M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$50.38M (FY 2016) to $651.56M. Figures come from the company's audited annual reports as filed with the SEC.
